Point72 Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Point72 Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.74M	Buy	398,463 +128,452	+48%	+$1.8M	0.01%	1558
2026 Q1	$3.46M	Buy	+270,011	New	+$3.44M	﹤0.01%	1946
2025 Q4	–	Sell	-174,261	Closed	-$2.4M	–	4086
2025 Q3	$3.01M	Buy	+174,261	New	+$2.15M	0.01%	1275
2021 Q2	–	Sell	-180,400	Closed	-$14.5M	–	1106
2021 Q1	$14.5M	Buy	180,400 +34,900	+24%	+$2.34M	0.07%	339
2020 Q4	$7.92M	Sell	145,500 -507,619	-78%	-$18.4M	0.04%	493
2020 Q3	$13M	Sell	653,119 -217,788	-25%	-$4.54M	0.07%	353
2020 Q2	$18.3M	Buy	+870,907	New	+$14.8M	0.12%	225

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Point72 Asset Management's NTLA Position: Q2 2026 in Review

Point72 Asset Management increased its Intellia Therapeutics (NTLA) stake by 48% in Q2 2026, buying an estimated $1.8M and bringing the position to 398,463 shares worth $6.74M. The position accounts for 0.01% of the portfolio, ranked #1558.

Point72 Asset Management first reported a position in NTLA in Q2 2020 and has held it in 7 quarters since. The position peaked at $18.3M in Q2 2020. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Point72 Asset Management held 398,463 shares of Intellia Therapeutics worth $6.74M as of Q2 2026.
Point72 Asset Management bought 128,452 Intellia Therapeutics shares in Q2 2026, an estimated $1.8M.
Intellia Therapeutics made up 0.01% of Point72 Asset Management's portfolio in Q2 2026, its #1558 holding.
Point72 Asset Management first reported a position in Intellia Therapeutics in Q2 2020 and has held it in 7 quarters since.
Point72 Asset Management's Intellia Therapeutics position peaked at $18.3M in Q2 2020.
329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.